Clinical Trial Update: Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating natalizumab in combination with glatiramer acetate in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)
• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED